Published by Josh White on 1st February 2022
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the successful completion of a preclinical safety study with a novel 'XF-73' dermal formulation on Tuesday.
URL: http://www.digitallook.com/dl/news/story/32432638/...